Literature DB >> 29674483

Influence of stent design and use of protection devices on outcome of carotid artery stenting: a pooled analysis of individual patient data.

Jean-Louis Mas1, Olav Jansen2, Leo H Bonati3,4, Fritz Wodarg2, Elisabeth L Turner5, Joanna Dobson5, Peter A Ringleb6, Willem P Mali7, Gustav Fraedrich8, Gilles Chatellier9, Jean-Pierre Bequemin10, Martin M Brown3, Ale Algra11.   

Abstract

BACKGROUND AND
PURPOSE: Carotid artery stenting is an alternative to endarterectomy for the treatment of symptomatic carotid stenosis but was associated with a higher risk of procedural stroke or death in randomized controlled trials (RCTs). Technical aspects of treatment may partly explain these results. The purpose of this analysis was to investigate the influence of technical aspects such as stent design or the use of protection devices, as well as clinical variables, on procedural risk.
METHODS: We pooled data of 1557 individual patients receiving stent treatment in three large RCTs comparing stenting versus endarterectomy for symptomatic carotid stenosis. The primary outcome event was any procedural stroke or death occurring within 30 days after stenting.
RESULTS: Procedural stroke or death occurred significantly more often with the use of open-cell stents (61/595 patients, 10.3%) than with closed-cell stents (58/962 patients, 6.0%; RR 1.76; 95% CI 1.23 to 2.52; P=0.002). Procedural stroke or death occurred in 76/950 patients (8.0%) treated with protection devices (predominantly distal filters) and in 43/607 (7.1%) treated without protection devices (RR 1.10; 95% CI 0.71 to 1.70; P=0.67). Clinical variables predicting the primary outcome event were age, severity of the qualifying event, history of prior stroke, and level of disability at baseline. The effect of stent design remained similar after adjustment for these variables.
CONCLUSIONS: In symptomatic carotid stenosis, the use of stents with a closed-cell design is independently associated with a lower risk of procedural stroke or death compared with open-cell stents. Filter-type protection devices do not appear to reduce procedural risk. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  carotid artery stenting; plaque; protection system; stent design; stent optimization

Mesh:

Year:  2018        PMID: 29674483     DOI: 10.1136/neurintsurg-2017-013622

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  4 in total

1.  Secular Trends in Procedural Stroke or Death Risks of Stenting Versus Endarterectomy for Symptomatic Carotid Stenosis.

Authors:  Mandy D Müller; Stefanie von Felten; Ale Algra; Jean-Pierre Becquemin; Richard Bulbulia; David Calvet; Hans-Henning Eckstein; Gustav Fraedrich; Alison Halliday; Jeroen Hendrikse; George Howard; John Gregson; Olav Jansen; Martin M Brown; Jean-Louis Mas; Thomas G Brott; Peter A Ringleb; Leo H Bonati
Journal:  Circ Cardiovasc Interv       Date:  2019-08-05       Impact factor: 6.546

2.  Evaluation of 3D printed carotid anatomical models in planning carotid artery stenting.

Authors:  Hakan Göçer; Ahmet Barış Durukan; Osman Tunç; Erdinç Naseri; Ertuğrul Ercan
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2020-04-22       Impact factor: 0.332

3.  Mid-term and late results of endovascular treatment for symptomatic carotid artery stenosis under proximal protection.

Authors:  Paweł Latacz; Marian Simka; Marcin Krzanowski; Katarzyna Krzanowska; Paweł Brzegowy; Bartłomiej Łasocha; Tadeusz J Popiela
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2020-04-20       Impact factor: 1.195

4.  Carotid Stenting without Embolic Protection Increases Major Adverse Events: Analysis of the National Surgical Quality Improvement Program.

Authors:  P Nazari; P Golnari; M C Hurley; A Shaibani; S A Ansari; M B Potts; B S Jahromi
Journal:  AJNR Am J Neuroradiol       Date:  2021-04-01       Impact factor: 4.966

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.